2025-07-05 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. The report is structured with numerical summaries followed by brief analytical comments.

**Johnson & Johnson (JNJ) Analysis**

**Ticker:** JNJ
**Company Description:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 14.93%
*   **VOO Cumulative Return:** 95.42%
*   **Absolute Deviation:** -80.49%
*   **Relative Deviation:** 2.1 (based on a range of max: 20.0, min: -83.0)

**Analysis:**

JNJ significantly underperformed the S&P 500 (VOO) over the period examined. The relative deviation suggests that this underperformance is near the lower end of its historical range compared to the S&P 500.
 **알파,베타 분석**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.1% | -1.0% | -0.0 | 336.2 |
| 2016-2018  | 8.0% | 56.6% | -10.0% | 0.0 | 310.5 |
| 2017-2019  | 18.0% | 56.6% | -12.0% | 0.7 | 351.0 |
| 2018-2020  | 12.0% | 59.2% | -8.0% | 0.3 | 378.7 |
| 2019-2021  | 32.0% | 59.6% | -16.0% | 0.2 | 411.6 |
| 2020-2022  | 7.0% | 61.4% | 5.0% | 0.2 | 425.0 |
| 2021-2023  | -15.0% | 61.4% | -33.0% | 0.4 | 377.1 |
| 2022-2024  | -35.0% | 61.4% | -61.0% | 0.3 | 348.0 |
| 2023-2025  | -12.0% | 70.1% | -60.0% | 0.2 | 375.4 |

**Analysis:**

The provided table shows that Johnson & Johnson(JNJ) has experienced varying performance across different periods.  The data indicates:

*   **CAGR (Compound Annual Growth Rate):** The CAGR has fluctuated significantly, with positive growth in earlier periods (e.g., 28.0% in 2015-2017) but negative growth in more recent years (e.g., -35.0% in 2022-2024).
*   **MDD (Maximum Drawdown):** MDD has generally increased over time, indicating higher risk and potential losses for investors.
*   **Alpha:** Alpha is mostly negative, suggesting that JNJ has generally underperformed its benchmark on a risk-adjusted basis. The negative Alpha values have become more pronounced in recent periods.
*   **Beta:** The Beta values are generally low (close to zero), indicating that JNJ's price is not strongly correlated with the broader market.
*   **Cap (Market Capitalization):** The market capitalization increased until 2020-2022 and has since declined, reflecting the recent negative performance.

**2. Recent Price Action**

*   **Last Price:** 156.01
*   **Previous Close:** 155.56
*   **Change:** 0.29
*   **5-day Moving Average:** 154.545
*   **20-day Moving Average:** 153.9017
*   **60-day Moving Average:** 153.7569

**Analysis:**

The stock price is currently above its 5, 20, and 60-day moving averages, suggesting a short-term upward trend. The slight price increase from the previous close indicates minor positive momentum.

**3. Indicators and Signals**

*   **Market Risk Indicator (MRI):** 0.3301 (Low Risk)
*   **RSI:** 47.8448
*   **PPO:** 0.2447
*   **Hybrid Signal:** cash_1%_Buy 80% of cash (21 shares - Caution - MRI:0.33) (Cash Ratio: 1% on 2025-07-03)
*   **Recent (20-day) Relative Deviation Change:** -4.2 (Indicates short-term decline)
*   **Expected Return (%):** -1391.2

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI of 47.84 is neutral, not indicating overbought or oversold conditions.
*   The PPO value suggests that the price is slightly above its moving average, indicating upward momentum.
*   The Hybrid Signal suggests a cautious buy signal, recommending deploying 80% of available cash.
*   The negative change in relative deviation indicates a short-term decline in performance relative to the benchmark.
*   The significantly negative Expected Return suggests a very pessimistic outlook for long-term performance relative to the S&P 500.

**4. Recent News & Events**

*   **[2025-07-05]:** JNJ has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-02]:** Analysts are discussing JNJ's recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-04]:** JNJ's stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-01]:** Market experts highlight both risks and opportunities for JNJ, advising investors to monitor recent news and company announcements.

**Analysis:**

Recent news suggests that JNJ is experiencing volatility and is subject to analyst scrutiny. It is important to follow the specific news to assess the impact on the company's performance.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
| :--------- | :--- | :--------- |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2025-04-23 | 1.35 | 21.38 B$ |

**Analysis:**

Earnings per share (EPS) has varied significantly over the observed quarters. Revenue has remained relatively stable, with fluctuations around the $22 billion mark. The most recent EPS figure (4.57) is notably higher than the previous quarters, which may be a positive sign, but the table include duplicated records.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |

**Capital and Profitability**

| Quarter    | Equity     | ROE     |
| :--------- | :--------- | :------ |
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80%  |
| 2024-09-30 | $70.16B   | 3.84%  |
| 2024-06-30 | $71.54B   | 6.55%  |
| 2024-03-31 | $70.02B   | 4.65%  |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable over the past five quarters, fluctuating between $21.38B and $22.52B.
*   **Profit Margin:** Profit margins have shown a slight decreasing trend from 69.55% to 66.40% over the period.
*   **Equity:** Equity has generally increased, with a notable rise in the most recent quarter.
*   **ROE (Return on Equity):** ROE has fluctuated, with the most recent quarter showing a significant increase to 14.08%, indicating improved profitability relative to equity.

**7. Overall Analysis**

Johnson & Johnson (JNJ) is currently showing mixed signals. While recent price action suggests short-term upward momentum and the MRI indicates a low-risk environment, the company has significantly underperformed the S&P 500. Recent news indicates increased volatility. Earnings and financial metrics present a mixed picture, with some positive signs in the most recent quarter but also some concerns about declining profit margins. The significantly negative Expected Return is a major red flag. Recent negative alpha, recent negative CAGR and recent increasing MDD are concerning.

**Recommendation:**

Based on this analysis, a cautious approach is warranted. Investors should carefully monitor the news and analyst reports for further insights into the company's prospects. Given the underperformance relative to the S&P 500 and the negative expected return, it may not be advisable to significantly increase JNJ holdings at this time. The Hybrid Signal suggests a modest buying opportunity, but with caution.
